The Challenges Faced by ASX Healthcare Stocks in 2026
In 2026, the Australian Securities Exchange (ASX) healthcare sector has experienced a significant downturn. Major players such as CSL Ltd, Cochlear Ltd, and ResMed Inc have all seen their share prices drop to multi-year lows. This decline is attributed to a combination of earnings downgrades, sector rotation, and macroeconomic headwinds that have shifted investor attention towards energy and resources stocks.
Despite these challenges, there are potential opportunities for investors who can look beyond short-term fluctuations. Here’s an overview of where each of these stocks stands today.
CSL Ltd: A Deep Dive into the Decline
CSL has faced an extraordinary fall in its share price this year. The company’s shares have dropped approximately 43% in 2026 and more than 60% over the past twelve months, reaching a 10-year low recently. The most recent catalyst was another guidance downgrade, with Interim CEO Gordon Naylor lowering FY2026 revenue expectations to approximately US$15.2 billion on a constant currency basis following a 90-day strategic review.
The market’s patience has run out, with management citing weakness in China albumin pricing, inventory normalisation in the US immunoglobulin market, and operational challenges as primary drivers. However, the bull case for CSL rests on its plasma-derived therapies business, which operates behind barriers to entry that no competitor has been able to meaningfully breach in decades.
Plasma collection volumes have recovered from post-COVID lows, and the Vifor integration is progressing. Additionally, insiders are now buying shares on the market for the first time in years, signaling that those closest to the business believe the selloff has gone too far. While the market demands proof of a sustained recovery, current valuations for CSL are at levels not seen since before the pandemic.
Cochlear Ltd: A Tough Year for the Hearing Technology Giant
Cochlear’s performance in 2026 has been even more challenging than CSL’s. The shares are down 62% year to date, hitting an eleven-year low in recent weeks. The April guidance downgrade, which cut FY2026 underlying net profit from $435 to $460 million down to $290 to $330 million, was one of the worst earnings cuts in the company’s listed history.
The causes were a mix of temporary and concerning factors. Hospital capacity constraints, reduced referral activity, and Middle East disruptions have pushed patients to delay surgery. Cost of living pressures in the US appear to be causing some patients to treat cochlear implants as discretionary rather than essential, at least in the short term. However, the long-term demand picture remains unchanged.
Cochlear holds approximately 50% global market share in cochlear implants, with just 3% penetration of an addressable market exceeding six million people in developed markets alone. Brokers including Jarden and Wilsons Advisory still see significant upside from current levels, with some flagging upside of more than 100% over twelve months. CEO Dig Howitt emphasized that the clinical need for cochlear implants continues to grow, particularly for the adult and seniors segment, and that cochlear implants are associated with a lower incidence of dementia.
Investors should note that surgeries are being delayed, not cancelled. This suggests that the long-term demand for cochlear implants remains strong.
ResMed Inc: Navigating the GLP-1 Concerns
ResMed’s 2026 selloff is being driven by fears about GLP-1 obesity drugs threatening demand for CPAP devices. However, these fears have proven to be significantly overstated. The company’s own data from 1.7 million patients shows that patients on both GLP-1 therapy and CPAP therapy actually show higher adherence rates than those on CPAP alone.
In Q3 FY2026, ResMed delivered revenue of US$1.29 billion, up 11% year-on-year, with operating income rising 22% and gross margins improving to 58.9%. CEO Mick Farrell stated that he believes GLP-1s are truly a megatrend and a once-in-a-generation demand-gen opportunity for ResMed Inc. Despite these positive fundamentals, the shares remain down approximately 22% in 2026 as sentiment lags the reality.
At current prices, ResMed trades materially below fair value according to analysts who have updated their models following the Q3 result.
Foolish Takeaway
CSL, Cochlear, and ResMed are three of the highest-quality healthcare businesses ever listed on the ASX. All three are dealing with headwinds that are temporary, cyclical, or based on fears that have not materialised. That does not mean the bottom is in, and near-term volatility will likely continue. But for investors with multi-year time horizons, the entry points available in each of these ASX healthcare stocks today look considerably more attractive than anything on offer in the past five years.
